Digoxin treatment does not reinduce radioiodine uptake in radioiodine refractory non-medullary thyroid carcinoma
Authors' conclusion
Contrary to results from preclinical trials, in this trial, 3 weeks of digoxin treatment did not reinduce RAI uptake in patients with NMTC. This highlights essential challenges regarding the approach toward optimization of studies aimed to restore the RAI uptake and its therapeutic efficacy through drug repurposing.
Study context
- Population
- Patients with metastasized radioactive iodine (RAI)-refractory non-medullary thyroid carcinoma (NMTC), included November 2022–June 20237 evaluable
- Participants
- 8 patients
- Outcome
- Clinically relevant RAI uptake on [123I]NaI scintigraphy after digoxin vs baseline
- Follow-up
- After 3 weeks of digoxin
Methodological detailssingle-center
- Single-center
Main finding
As reported in the abstract
Clinically relevant RAI uptake after digoxin · 3 weeks
Digoxin
0
events
- None of the 7 evaluable patients showed clinically relevant RAI uptake after digoxin
- 0 of 7
Observational data: associations, not effects.
Safety
- No digoxin-related serious adverse events occurred
Original publication
Digoxin treatment does not reinduce radioiodine uptake in radioiodine refractory non-medullary thyroid carcinoma. Eur Thyroid J. Published 19 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →